Stuttgart - Delayed Quote EUR

Amneal Pharmaceuticals Inc (2DT.SG)

6.55

-0.05

(-0.76%)

As of 8:00:56 AM GMT+2. Market Open.

Amneal and Apiject to Expand Sterile and Blow-Fill-Seal (BFS) Capabilities for Advanced Pharmaceutical Manufacturing in the U.S.

-Adds BFS platform technology to provide large-scale production capacity for sterile drug dosage forms, including injectables, ophthalmics and inhalation -Expands Amneal’s extensive domestic pharmaceutical manufacturing footprint BRIDGEWATER, N.J., May 08, 2025 (GLOBE NEWSWIRE) -- Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX) (“Amneal” or the “Company”), an American biopharmaceutical company, and Apiject Systems, Corp. (“Apiject”), a medical technology company focused on advanced drug delivery, to

GlobeNewswire 6 days ago

AMRX
Amneal Pharmaceuticals Inc (AMRX) Q1 2025 Earnings Call Highlights: Strong Growth and Strategic ...

Amneal Pharmaceuticals Inc (AMRX) reports robust revenue growth and outlines strategic initiatives for biosimilars and international expansion.

GuruFocus.com 11 days ago

AMRX
Amneal Reports First Quarter 2025 Financial Results

BRIDGEWATER, N.J., May 02, 2025--AMNEAL REPORTS FIRST QUARTER 2025 FINANCIAL RESULTS

Business Wire 12 days ago

AMRX
Even though Amneal Pharmaceuticals (NASDAQ:AMRX) has lost US$78m market cap in last 7 days, shareholders are still up 125% over 5 years

It might be of some concern to shareholders to see the Amneal Pharmaceuticals, Inc. ( NASDAQ:AMRX ) share price down...

Simply Wall St. 27 days ago

AMRX
Amneal Donates $1.5 Million to Support Patients During Parkinson’s Awareness Month

BRIDGEWATER, N.J., April 11, 2025--Amneal Donates $1.5 Million to Support Patients During Parkinson’s Awareness Month

Business Wire last month

AMRX
Amneal to Report First Quarter 2025 Results on May 2, 2025

BRIDGEWATER, N.J., April 08, 2025--Amneal to Report First Quarter 2025 Results on May 2, 2025

Business Wire last month

AMRX
Amneal Announces New Data from Phase 3 Study Showing Significant Improvements in Sleep Quality with CREXONT® (Carbidopa and Levodopa) Extended-Release Capsules in Parkinson’s Disease

BRIDGEWATER, N.J., April 07, 2025--New Data from Phase 3 Study Showing Significant Improvements in Sleep Quality with CREXONT® Extended-Release Capsules in Parkinson’s Disease.

Business Wire last month

AMRX
Amneal Announces Expanded Coverage for CREXONT® (Carbidopa and Levodopa) to Enhance Access for Parkinson’s Disease Patients in the U.S.

BRIDGEWATER, N.J., April 03, 2025--Amneal Announces Expanded Coverage for CREXONT® (Carbidopa and Levodopa) to Enhance Access for Parkinson’s Disease Patients in the U.S.

Business Wire last month

AMRX
Amneal Launches BORUZU™, First Ready-to-Use Bortezomib Injection for Multiple Myeloma and Mantle Cell Lymphoma

BRIDGEWATER, N.J., April 01, 2025--Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX) ("Amneal" or the "Company"), a global biopharmaceutical company, and Shilpa Medicare Limited ("Shilpa") today announced the U.S. launch of BORUZU™, a new presentation of bortezomib for ready-to-use subcutaneous administration or intravenous (IV) administration. This new ready-to-use oncology product reduces the compounding preparation steps typically required with administration.

Business Wire last month

AMRX
Amneal to Participate at Upcoming Investor Conference

BRIDGEWATER, N.J., March 10, 2025--Amneal to Participate at Upcoming Investor Conference

Business Wire 2 months ago

AMRX
Amneal’s BLA Submissions for Two Denosumab Biosimilars Accepted for Review by U.S. FDA

BRIDGEWATER, N.J., March 03, 2025--Amneal’s BLA Submissions for Two Denosumab Biosimilars Accepted for Review by U.S. FDA

Business Wire 2 months ago

AMRX
Amneal Pharmaceuticals Full Year 2024 Earnings: EPS Misses Expectations

Amneal Pharmaceuticals ( NASDAQ:AMRX ) Full Year 2024 Results Key Financial Results Revenue: US$2.79b (up 17% from FY...

Simply Wall St. 2 months ago

AMRX
Amneal Reports Fourth Quarter and Full Year 2024 Financial Results

BRIDGEWATER, N.J., February 28, 2025--Amneal Reports Fourth Quarter and Full Year 2024 Financial Results

Business Wire 2 months ago

AMRX
Amneal Launches Mesalamine and Receives U.S. FDA Approval for Lenalidomide

BRIDGEWATER, N.J., February 19, 2025--Amneal Launches Mesalamine and Receives U.S. FDA Approval for Lenalidomide

Business Wire 2 months ago

AMRX
Although Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) insiders have sold lately, they have the highest ownership with 51% stake

Key Insights Amneal Pharmaceuticals' significant insider ownership suggests inherent interests in company's expansion...

Simply Wall St. 2 months ago

AMRX
7MM PD market to grow by $4.5bn between 2023 and 2033

Growth will be driven by advancements in innovative therapies, including the first DMTs, and a growing patient population.

Clinical Trials Arena 3 months ago

AMRX

ACHC

SUPN
Amneal to Report Fourth Quarter and Full Year 2024 Results on February 28, 2025

BRIDGEWATER, N.J., January 29, 2025--Amneal to Report Fourth Quarter and Full Year 2024 Results on February 28, 2025

Business Wire 3 months ago

AMRX
Kashiv Biosciences’ Phase I trial of KSHB002 injection meets primary endpoints

The biosimilar's safety and immunogenicity profiles were found to be comparable to those of the reference product in the trial.

Clinical Trials Arena 3 months ago

AMRX
Amneal Receives U.S. FDA Approval for Memantine/Donepezil Extended-Release Capsules and Everolimus Tablets for Oral Suspension, and Tentative U.S. FDA Approval for Rifaximin

BRIDGEWATER, N.J., January 23, 2025--Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX) ("Amneal" or the "Company") today announced that the U.S. Food and Drug Administration (FDA) has approved memantine/donepezil 14-10 mg and 28-10 mg extended-release capsules, which references Abbvie’s NAMZARIC®, and Everolimus 2 mg, 3 mg and 5 mg extended-release capsules, which references Novartis’ AFINITOR DISPERZ®. In addition, the FDA has granted tentative approval to Amneal’s rifaximin 550 mg oral tablets, whic

Business Wire 3 months ago

AMRX
Amneal to Participate at Upcoming Investor Conferences

BRIDGEWATER, N.J., December 04, 2024--Amneal to Participate at Upcoming Investor Conferences

Business Wire 5 months ago

AMRX

Performance Overview

Return	2DT.SG	S&P 500 (^GSPC)
YTD	-10.27%	+0.08%
1-Year	+5.65%	+12.20%
3-Year	+100.92%	+46.29%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Amneal Pharmaceuticals Inc (2DT.SG)

Amneal and Apiject to Expand Sterile and Blow-Fill-Seal (BFS) Capabilities for Advanced Pharmaceutical Manufacturing in the U.S.

Amneal Pharmaceuticals Inc (AMRX) Q1 2025 Earnings Call Highlights: Strong Growth and Strategic ...

Amneal Reports First Quarter 2025 Financial Results

Even though Amneal Pharmaceuticals (NASDAQ:AMRX) has lost US$78m market cap in last 7 days, shareholders are still up 125% over 5 years

Amneal Donates $1.5 Million to Support Patients During Parkinson’s Awareness Month

Amneal to Report First Quarter 2025 Results on May 2, 2025

Amneal Announces New Data from Phase 3 Study Showing Significant Improvements in Sleep Quality with CREXONT® (Carbidopa and Levodopa) Extended-Release Capsules in Parkinson’s Disease

Amneal Announces Expanded Coverage for CREXONT® (Carbidopa and Levodopa) to Enhance Access for Parkinson’s Disease Patients in the U.S.

Amneal Launches BORUZU™, First Ready-to-Use Bortezomib Injection for Multiple Myeloma and Mantle Cell Lymphoma

Amneal to Participate at Upcoming Investor Conference

Amneal’s BLA Submissions for Two Denosumab Biosimilars Accepted for Review by U.S. FDA

Amneal Pharmaceuticals Full Year 2024 Earnings: EPS Misses Expectations

Amneal Reports Fourth Quarter and Full Year 2024 Financial Results

Amneal Launches Mesalamine and Receives U.S. FDA Approval for Lenalidomide

Although Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) insiders have sold lately, they have the highest ownership with 51% stake

7MM PD market to grow by $4.5bn between 2023 and 2033

Amneal to Report Fourth Quarter and Full Year 2024 Results on February 28, 2025

Kashiv Biosciences’ Phase I trial of KSHB002 injection meets primary endpoints

Amneal Receives U.S. FDA Approval for Memantine/Donepezil Extended-Release Capsules and Everolimus Tablets for Oral Suspension, and Tentative U.S. FDA Approval for Rifaximin

Amneal to Participate at Upcoming Investor Conferences

Performance Overview